Evidence map›Paper›PMID 40536269›Full record

ReviewThe oncologist2025

Oligometastatic pancreatic cancer: current state of management and emerging therapies.

Andrii Khomiak, Nicole B Balmaceda, Sumaya A Ghaffar, Christopher H Lieu, Marco Del Chiaro, Wells A Messersmith, Robert W Lentz

Abstract readReview
In one paragraph

Review in The oncologist, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Andrii KhomiakDivision of Surgical Oncology, Department of Surgery, University of Colorado School of Medicine, Aurora, CO 80045, USA.ORCID 0000-0003-0974-4965
Nicole B BalmacedaDivision of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, CO 80045, USA.
Sumaya A GhaffarDivision of Surgical Oncology, Department of Surgery, University of Colorado School of Medicine, Aurora, CO 80045, USA.
Christopher H LieuDivision of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, CO 80045, USA.
Marco Del ChiaroDivision of Surgical Oncology, Department of Surgery, University of Colorado School of Medicine, Aurora, CO 80045, USA.
Wells A MessersmithDivision of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, CO 80045, USA.
Robert W LentzDivision of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, CO 80045, USA.ORCID 0000-0002-7207-8195

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oligometastatic pancreatic cancer is a distinct clinical entity with limited metastatic burden. This unique subset of patients harbor a favorable tumor biology and potentially better prognosis compared to widespread metastatic disease. This review explores definitions of oligometastatic pancreatic cancer and the current state of management, including systemic therapy, surgery, and locoregional techniques. While there are few randomized clinical trials directing the management of oligometastatic pancreatic cancer, we provide insights into the treatment challenges, evolving therapeutic approaches, and future directions for this unique subset of patients.

Indexed as

Pancreatic NeoplasmsHumansNeoplasm Metastasislocoregional therapymetastasis-directed therapyoligometastatic diseasepancreatic ductal adenocarcinomasurgical metastasectomysystemic therapy

Identifiers

PMID40536269
PMCPMC12204394

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.